Trial Profile
Dose-escalation Study of Graft-versus-host Disease Prophylaxis With High-dose Post-transplantation Bendamustine in Patients With Refractory Acute Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Busulfan; Fludarabine; Mycophenolate mofetil; Tacrolimus
- Indications Acute myeloid leukaemia; Graft-versus-host disease; Leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 01 Jul 2021 Results assessing the optimal dose of PTB and evaluate the antileukemic effect of HSCT with this type of graft-versus-host disease (GVHD) prophylaxis published in the Transplantation and Cellular Therapy
- 19 Nov 2020 Status changed from recruiting to completed.
- 16 Mar 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.